

REMARKS

Claims 23-24 and 29-38 are pending after entry of the amendments set forth herein. Claims 1-22 and 25-28 are canceled without prejudice as being drawn to a non-elected invention. Claims 23 and 29 are amended. New claims 30-38 are added. Support for these amendments is found in the specification at paragraph [50], which recites "The peptides and proteins of the invention can also be used to generate other useful reagents of the invention, including monoclonal and polyclonal antibody-producing cell lines and antibodies derived therefrom in isolated and purified form". Paragraph [33] provides support in the recitation "the multivalent gluten oligopeptides described herein, including those comprising SEQ ID NO:12; deamidated counterparts, derivatives, analogs, and conservatively modified variants thereof, are useful . . . for producing antibodies that bind specifically to such oligopeptides for their detection". No new matter is added.

Objections to the Claims and Specification

The informalities in the published specification noted by the Examiner are corrected herein. Withdrawal of the objection is requested.

Claims 23-24 are objected to because of informalities. Applicants have introduced the specific polypeptide sequences into the claims, as suggested by the Examiner. Applicants have further added Claim 30 and 35-38, which recites the method by which the antibody producing cell line is generated. Withdrawal of the objection is requested.

Rejections Under §103(a)

Claims 23-24 and 29 have been rejected under 35 U.S.C. 103(a) as being unpatentable over Anderson *et al.* (WO 03104273) in view of Lewicki *et al.* (US 4656253). Applicants respectfully submit that the presently claimed invention is not taught or suggested by the cited art. The present claims are directed to antibodies and antibody producing cells lines that specifically recognize the 33mer oligopeptide set forth in SEQ ID NO:12 or specific conjugates and derivatives thereof. This specific oligopeptide is not disclosed in the cited art.

Applicants note for the Examiner's consideration that Claims 30 and 35-38 are directed to antibodies specifically raised by a response to the peptide of SEQ ID NO:12, or specific conjugates and derivatives thereof. Such cell lines and antibodies are not taught or suggested by the cited art.

In view of the above amendments and remarks, withdrawal of the rejection is requested.

Claims 23-24 and 29 have been rejected under 35 U.S.C. 103(a) as being unpatentable over Arentz-Hansen et al. (J. Exp. Med. 2000 Vol. 191, page 603-612; Applicant submitted IDS information) in view of Lewicki et al. Applicants respectfully submit that the presently claimed invention is not taught or suggested by the cited art. The present claims are directed to antibodies and antibody producing cells lines that specifically recognize the 33mer oligopeptide set forth in SEQ ID NO:12 or specific conjugates and derivatives thereof. This specific oligopeptide is not disclosed in the cited art.

Applicants note for the Examiner's consideration that Claims 30 and 35-38 are directed to antibodies specifically raised by a response to the peptide of SEQ ID NO:12, or specific conjugates and derivatives thereof. Such cell lines and antibodies are not taught or suggested by the cited art.


In view of the above amendments and remarks, withdrawal of the rejection is requested.

Applicant submits that all of the claims are in condition for allowance, which action is requested. If the Examiner finds that a telephone conference would expedite the prosecution of this application, please telephone the undersigned at the number provided.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number STAN-258US5.

Respectfully submitted,
BOZICEVIC, FIELD &
FRANCIS LLP

Date: March 6, 2009

By: 
Pamela J. Sherwood, Ph.D.
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231